SHOX2

Across TCGA pan-cancer cohorts, SHOX2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SHOX2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SHOX2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHOX2 expression acts as an unfavorable survival marker.

HNSC, BLCA, and SKCM are the cancer types where SHOX2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.186	0.672	.005	36	view →
BLCA	OS	Median	III,IV	0.188	0.581	.005	9	view →
SKCM	DFS	Median	All	0.325	0.617	.023	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SHOX2–HNSC (OS)

Open the HNSC breakdown →